SCHEMBL1461892

SCHEMBL1461892

Cc1nnnn1-c1ccc(C#N)cn1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
FLT3 P36888 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
MAPT P10636 2/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
CYP11B2 P19099 1/20 0.36
SMO Q99835 3/20 0.36
GPR119 Q8TDV5 1/20 0.36
MAOB P27338 1/20 0.35
USP2 O75604 1/20 0.35
PANK3 Q9H999 6/20 0.35
HSD17B10 Q99714 1/20 0.35
GRM4 Q14833 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15116391 0.78 GRIN2D (0.41) ALDH1A1L3MBTL1MAPTHTTP2RX7
SCHEMBL23976747 0.78 KDM4E (0.58) ALDH1A1KDM4EL3MBTL1FLT3IRAK4
SCHEMBL25778685 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL1FLT3IRAK4
SCHEMBL1163513 0.76 GRIN2D (0.39) ALDH1A1KDM4EHTT
SCHEMBL15114558 0.73 LMNA (0.34) ALDH1A1MAPTTSHRHTTSMO
SCHEMBL1461643 0.73 KDM4E (0.61) ALDH1A1KDM4EL3MBTL1FLT3IRAK4
SCHEMBL18789253 0.72 KDM4E (0.59) ALDH1A1KDM4EL3MBTL1
SCHEMBL12825103 0.72 KDM4E (0.55) ALDH1A1KDM4EL3MBTL1FLT3IRAK4
SCHEMBL24724300 0.71 LMNA (0.33)
SCHEMBL24724303 0.71 KCNJ1 (0.56) ALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
EP-2475653-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS Bayer Pharma Aktiengesellschaft (DE) 2012-07-18 EP disclosed
WO-2011029537-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-17 WO disclosed
WO-2011029537-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins TPMT, BPHL, VHL ALDH1A1 186/4885KDM4E 2244/4885L3MBTL1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.